Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL

Nurix Therapeutics

Nurix Therapeutics

NRIX

0.00
  • Nurix flagged updated Phase 1a/b results for bexobrutideg, a BTK degrader for CLL/SLL, scheduled for presentation at the 2026 EHA Congress.
  • Heavily pretreated relapsed or refractory patients showed durable responses, supporting continued development despite prior exposure to multiple standard therapies.
  • Earlier-line cohorts showed strong anti-tumor activity, including patients who had progressed on a BTK inhibitor but had not used a BCL2 inhibitor.
  • The safety profile remained broadly consistent with prior disclosures, with tolerability supporting longer treatment duration and expansion into broader studies.
  • Nurix said the readout underpins plans for a broad Phase 3 monotherapy program, with combination regimens also under evaluation alongside a Roche collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110700PRIMZONEFULLFEED9735379) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.